Regulatory press release6/25/2025, 3:00 PMDelisting of the shares of Scandion Oncology - last day of trading July 11, 2025
Regulatory press release6/25/2025, 12:00 PMScandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market
Regulatory press release3/27/2025, 3:00 PMScandion Oncology Announces Results of Annual General Meeting
Regulatory press release3/12/2025, 12:10 PMScandion Oncology – Notice convening the Annual General Meeting
Regulatory press release2/26/2025, 5:40 PMScandion Oncology CEO Francois Martelet, MD will take over CMO tasks
Regulatory press release2/26/2025, 5:35 PMScandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report
Regulatory press release2/26/2025, 5:30 PMScandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting
Regulatory press release1/13/2025, 6:00 AMScandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer
Regulatory press release11/20/2024, 4:30 PMWarrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million
Regulatory press release11/14/2024, 7:30 AMLast day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024
Press release11/5/2024, 4:00 PMInvitation to Scandion Oncology webcast and conference call November 11, 2024
Regulatory press release11/4/2024, 7:30 AMScandion Oncology announces the start of the exercise period for warrants of series TO 2
Regulatory press release10/31/2024, 7:30 AMCorrection: Scandion Oncology announces exercise price for warrants of series TO 2
Regulatory press release10/30/2024, 4:00 PMScandion Oncology announces exercise price for warrants of series TO 2